BioSpace News Archive

SwanBio Therapeutics to Present Preclinical Data on Lead Candidate at American Society of Gene & Cell Therapy 2022 Annual Meeting in Washington, DC May 16-19.

ImmPACT Bio USA , Inc. today announced the appointment of Venkata (Venkat) P. Yepuri as chief operating officer.

Hesperos Inc., pioneers of Human-on-a-Chip® in vitro systems, announced the publication of a peer-reviewed article showing that a Human-on-a-Chip® cell-based system recapitulates the neurophysiological characteristics of two rare autoimmune demyelinating neuropathies and demonstrate its potential use to evaluate novel therapeutics.

Cyclacel Pharmaceuticals, Inc. announced dosing of the first patient in the Company’s streamlined, multi-cohort Phase 1/2 study of oral CYC140 in patients with advanced solid tumors and lymphomas.

Altamira Therapeutics Ltd. announced that that it has reached the midpoint for enrollment in its COVAMID clinical investigation of its Bentrio™ nasal spray in patients with acute COVID-19.

Synaptogenix, Inc. (Nasdaq: SNPX) (“the Company”), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it has completed enrolling its target of 100 patients for its ongoing National Institutes of Health (“NIH”) sponsored Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer’s disease (“AD”).

RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that it submitted an Investigational New Drug Application (IND) for an observational study to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

As a member of the initiative, Pangaea will apply its novel unsupervised natural language processing, natural language generation and automatic machine learning frameworks to address important issues in healthcare in a privacy preserving manner.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), announced today that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (“CDSCO”) in India to manufacture and sell its SARAQ™ Hepatitis C (“HCV”) Viral Load Kit as an in vitro diagnostic (“IVD”).

Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2022 financial results on Thursday, April 28, 2022.